<DOC>
	<DOCNO>NCT00217620</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sorafenib work treat patient advanced soft tissue sarcoma .</brief_summary>
	<brief_title>S0505 Sorafenib Treating Patients With Advanced Soft Tissue Sarcomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate ( confirm , complete , partial ) patient advance soft tissue sarcoma treat sorafenib . - Determine 4-month progression-free survival rate patient treat drug . - Determine frequency severity adverse event patient treated drug . OTHER OBJECTIVES ( fund permit ) : - Correlate , preliminarily , decrease standard uptake variable ( SUV ) target lesion positron-emission tomography scan 4 week response patient treated drug . - Correlate , preliminarily , phosphorylation status KIT , PDGFR , VEGFR , raf/mek/erk pathway response patient treated drug . - Correlate , preliminarily , common B-raf kinase mutation response patient treated drug . OUTLINE : This multicenter study . Patients stratify accord histology ( leiomyosarcoma v liposarcoma v angiosarcoma , hemangiosarcoma , hemangiopericytoma ) . Patients receive oral sorafenib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 8 week disease progression every 6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 45-75 patient ( 15-25 per stratum ) accrue study within 15-38 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma 1 follow histology : Angiosarcoma , cutaneous visceral Malignant hemangiosarcoma Malignant hemangiopericytoma Grade 34 leiomyosarcoma Grade 34 liposarcoma Must evidence unresectable residual disease , metastatic disease , recurrent disease radiography Measurable disease xray , scan , physical examination Archived paraffinembedded tumor section available No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN due liver metastasis ) Bilirubin normal ( ≤ 2.5 time ULN due liver metastasis ) PT , PTT , INR normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No history thromboembolic disease No uncontrolled hypertension Other Not pregnant nursing Fertile patient must use effective contraception Able swallow oral medication No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 28 day since prior chemotherapy ( 42 day carmustine mitomycin ) recover Prior adjuvant chemotherapy allow No 1 prior chemotherapy regimen metastatic disease Endocrine therapy Not specify Radiotherapy At least 28 day since prior radiotherapy recover Must evidence disease progression within , measurable disease outside , radiation field completion radiotherapy Surgery At least 28 day since prior major surgery recover Other No prior sorafenib No prior inhibitor VEGFR MAPK pathway No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent therapeutic anticoagulation No concurrent administration follow medication : Rifampin Hypericum perforatum ( St. John 's wort ) Cytochrome P450 enzymeinducing antiepileptic drug , include follow : Phenytoin Carbamazepine Phenobarbital</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>